REPAIR-lab, Institute of Pathology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):291-9. doi: 10.1016/j.addr.2011.01.009. Epub 2011 Jan 31.
The endothelial cell (EC) is practically ubiquitous in the human body and forms the inner cellular lining of the entire cardiovascular system. Following tissue injury, the microcirculation becomes the stage for both the inflammatory response and the subsequent healing reaction to restore physiological function to the damaged tissue. The advent of the multidisciplinary field of Regenerative Medicine (RegMed), of which Tissue Engineering (TE) and drug delivery using modern stimuli-responsive or interactive biomaterials are important components, has opened up new approaches to the acceleration of the healing response. A central and rate-limiting role in the latter is played by the process of vascularization or neovascularization, so that it is not surprising that in RegMed concepts have been developed for the drug- and gene-delivery of potent stimuli such as vascular-endothelial growth factor (VEGF) to promote neovessel development. However, not all of these novel materials can be tested in vivo, and in vitro co-culture model systems using human primary cells are being developed to pre-evaluate and determine which of the RegMed concepts exhibit the most promising potential for success after implantation. This review describes some of the growing number of in vitro co-cultures model systems that are being used to study cell-cell and cell-material interactions at the cellular and molecular levels to determine which materials are best suited to integrate into the host, promote a rapid vascularization and fit into the regenerative process without disturbing or slowing the normal healing steps.
内皮细胞(EC)在人体中几乎无处不在,形成整个心血管系统的内层细胞衬里。在组织损伤后,微循环成为炎症反应和随后的修复反应的舞台,以恢复受损组织的生理功能。再生医学(RegMed)多学科领域的出现,其中组织工程(TE)和使用现代刺激响应或相互作用生物材料的药物输送是重要组成部分,为加速修复反应开辟了新途径。在后者中,血管生成或新生血管形成起着核心和限速作用,因此毫不奇怪,在 RegMed 概念中已经开发出了用于药物和基因输送的有效刺激物,如血管内皮生长因子(VEGF),以促进新血管的发育。然而,并非所有这些新型材料都可以在体内进行测试,正在开发使用人原代细胞的体外共培养模型系统,以预先评估和确定在植入后哪些 RegMed 概念表现出最有前途的成功潜力。这篇综述描述了一些越来越多的体外共培养模型系统,这些系统用于在细胞和分子水平上研究细胞-细胞和细胞-材料相互作用,以确定哪些材料最适合整合到宿主中,促进快速血管生成并适应再生过程,而不会干扰或减缓正常的愈合步骤。